vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and KILROY REALTY CORP (KRC). Click either name above to swap in a different company.
KILROY REALTY CORP is the larger business by last-quarter revenue ($272.2M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 6.3%, a 4.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -5.0%). KILROY REALTY CORP produced more free cash flow last quarter ($450.3M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -1.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
ANIP vs KRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $272.2M |
| Net Profit | $27.5M | $17.1M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 6.3% |
| Revenue YoY | 29.6% | -5.0% |
| Net Profit YoY | 367.5% | -73.7% |
| EPS (diluted) | $1.14 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $272.2M | ||
| Q3 25 | $227.8M | $279.7M | ||
| Q2 25 | $211.4M | $289.9M | ||
| Q1 25 | $197.1M | $270.8M | ||
| Q4 24 | $190.6M | $286.4M | ||
| Q3 24 | $148.3M | $289.9M | ||
| Q2 24 | $138.0M | $280.7M | ||
| Q1 24 | $137.4M | $278.6M |
| Q4 25 | $27.5M | $17.1M | ||
| Q3 25 | $26.6M | $162.3M | ||
| Q2 25 | $8.5M | $79.6M | ||
| Q1 25 | $15.7M | $43.7M | ||
| Q4 24 | $-10.3M | $65.0M | ||
| Q3 24 | $-24.2M | $57.7M | ||
| Q2 24 | $-2.3M | $54.5M | ||
| Q1 24 | $18.2M | $55.7M |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 14.8% | — |
| Q4 25 | 11.1% | 6.3% | ||
| Q3 25 | 11.7% | 58.0% | ||
| Q2 25 | 4.0% | 27.4% | ||
| Q1 25 | 8.0% | 16.1% | ||
| Q4 24 | -5.4% | 22.7% | ||
| Q3 24 | -16.3% | 19.9% | ||
| Q2 24 | -1.7% | 19.4% | ||
| Q1 24 | 13.2% | 20.0% |
| Q4 25 | $1.14 | $0.11 | ||
| Q3 25 | $1.13 | $1.31 | ||
| Q2 25 | $0.36 | $0.57 | ||
| Q1 25 | $0.69 | $0.33 | ||
| Q4 24 | $-0.45 | $0.50 | ||
| Q3 24 | $-1.27 | $0.44 | ||
| Q2 24 | $-0.14 | $0.41 | ||
| Q1 24 | $0.82 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $5.4B |
| Total Assets | $1.4B | $10.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $179.3M | ||
| Q3 25 | $262.6M | $372.4M | ||
| Q2 25 | $217.8M | $193.1M | ||
| Q1 25 | $149.8M | $146.7M | ||
| Q4 24 | $144.9M | $165.7M | ||
| Q3 24 | $145.0M | $625.4M | ||
| Q2 24 | $240.1M | $835.9M | ||
| Q1 24 | $228.6M | $855.0M |
| Q4 25 | $540.7M | $5.4B | ||
| Q3 25 | $505.8M | $5.5B | ||
| Q2 25 | $436.8M | $5.4B | ||
| Q1 25 | $418.6M | $5.4B | ||
| Q4 24 | $403.7M | $5.4B | ||
| Q3 24 | $405.9M | $5.4B | ||
| Q2 24 | $455.8M | $5.4B | ||
| Q1 24 | $452.0M | $5.4B |
| Q4 25 | $1.4B | $10.9B | ||
| Q3 25 | $1.4B | $11.0B | ||
| Q2 25 | $1.3B | $10.9B | ||
| Q1 25 | $1.3B | $10.9B | ||
| Q4 24 | $1.3B | $10.9B | ||
| Q3 24 | $1.3B | $11.4B | ||
| Q2 24 | $920.8M | $11.5B | ||
| Q1 24 | $914.5M | $11.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $566.3M |
| Free Cash FlowOCF − Capex | $29.1M | $450.3M |
| FCF MarginFCF / Revenue | 11.8% | 165.4% |
| Capex IntensityCapex / Revenue | 0.5% | 42.6% |
| Cash ConversionOCF / Net Profit | 1.10× | 33.10× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $833.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $566.3M | ||
| Q3 25 | $44.1M | $176.6M | ||
| Q2 25 | $75.8M | $143.7M | ||
| Q1 25 | $35.0M | $136.9M | ||
| Q4 24 | $15.9M | $541.1M | ||
| Q3 24 | $12.5M | $176.3M | ||
| Q2 24 | $17.4M | $88.7M | ||
| Q1 24 | $18.3M | $167.9M |
| Q4 25 | $29.1M | $450.3M | ||
| Q3 25 | $38.0M | $148.7M | ||
| Q2 25 | $71.8M | $118.4M | ||
| Q1 25 | $32.5M | $115.6M | ||
| Q4 24 | $13.5M | $440.8M | ||
| Q3 24 | $7.7M | $147.2M | ||
| Q2 24 | $13.0M | $69.5M | ||
| Q1 24 | $13.7M | $151.9M |
| Q4 25 | 11.8% | 165.4% | ||
| Q3 25 | 16.7% | 53.1% | ||
| Q2 25 | 34.0% | 40.9% | ||
| Q1 25 | 16.5% | 42.7% | ||
| Q4 24 | 7.1% | 153.9% | ||
| Q3 24 | 5.2% | 50.8% | ||
| Q2 24 | 9.4% | 24.7% | ||
| Q1 24 | 10.0% | 54.5% |
| Q4 25 | 0.5% | 42.6% | ||
| Q3 25 | 2.7% | 10.0% | ||
| Q2 25 | 1.9% | 8.7% | ||
| Q1 25 | 1.3% | 7.9% | ||
| Q4 24 | 1.3% | 35.0% | ||
| Q3 24 | 3.2% | 10.1% | ||
| Q2 24 | 3.2% | 6.8% | ||
| Q1 24 | 3.3% | 5.7% |
| Q4 25 | 1.10× | 33.10× | ||
| Q3 25 | 1.66× | 1.09× | ||
| Q2 25 | 8.87× | 1.81× | ||
| Q1 25 | 2.23× | 3.13× | ||
| Q4 24 | — | 8.32× | ||
| Q3 24 | — | 3.06× | ||
| Q2 24 | — | 1.63× | ||
| Q1 24 | 1.00× | 3.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
KRC
Segment breakdown not available.
